(4/10, Rosa) reported, “The addition of trastuzumab (Herceptin) to carboplatin and paclitaxel resulted in a significant survival benefit in women with advanced or recurrent, HER2-positive uterine serous carcinoma, with the greatest benefit observed in those with stage III/IV disease who received the regimen up front,” updated phase 2 data demonstrate. In addition, the regimen “led to increased PFS benefit in those with stage III/IV disease who were undergoing primary treatment (n = 41), with a median 17.7 months versus 9.3 months” among patients in the control cohort. Findings were released for the virtual SGO 2020 Annual Meeting.
